Open Access

VIEWPOINT

Production of mesenchymal stem cell derived-secretome as cell-free regenerative therapy and immunomodulation: A biomanufacturing perspective

by FUAD GANDHI TORIZAL^1,2,*, FRANSISCUS FIANO ANTHONY KERANS³, ANNISA KHUMAIRA¹

1 Department of Biotechnology, Faculty of Science and Technology, Universitas 'Aisyiyah Yogyakarta, Yogyakarta, 55292, Indonesia
2 Department of Bioengineering and Department of Chemical Systems Engineering, Graduate School of Engineering, The University of Tokyo, Tokyo, 1138654, Japan
3 Department of Physiology and Biochemistry, Faculty of Medicine and Health Science, Warmadewa University, Bali, 80239, Indonesia

* Corresponding Author: Fuad Gandhi Torizal,

(This article belongs to the Special Issue: Mesenchymal Stem Cells, Secretome and Biomaterials: Regenerative Medicine Application)

BIOCELL 2022, 46(8), 1885-1891. https://doi.org/10.32604/biocell.2022.019591

Received 30 September 2021; Accepted 08 December 2021; Issue published 22 April 2022

Abstract

The potential of mesenchymal stem cells (MSCs) in regenerative medicine has been largely known due to their capability to induce tissue regeneration in vivo with minimum inflammation during implantation. This adult stem cell type exhibit unique features of tissue repair mechanism and immune modulation mediated by their secreted factors, called secretome. Recently, the utilization of secretome as a therapeutic agent provided new insight into cell-free therapy. Nevertheless, a sufficient amount of secretome is necessary to realize their applications for translational medicine which required a proper biomanufacturing process. Several factors related to their production need to be considered to produce a clinical-grade secretome as a biological therapeutic agent. This viewpoint highlights the current challenges and considerations during the biomanufacturing process of MSCs secretome.

---

Keywords

---